Clinical Trials Sponsored by Theagenio Cancer Hospital

Total 9768 results

Zhejiang Cancer Hospital

Unknown

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

Small Cell Carcinoma of Lung

China
Zhejiang Cancer Hospital

Unknown

Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Zhejiang Cancer Hospital

Unknown

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
Zhejiang Cancer Hospital

Unknown

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Unknown

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0901)

Non-small Cell Lung Cancer

China
Taian Cancer Hospital

Unknown

Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma

Esophageal Carcinoma

China
Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Elderly Patients | Immunotherapy | Sintilimab | Chemoradiotherapy
Henan Cancer Hospital

Recruiting

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Extensive Small Cell Lung Cancer

China
Hunan Cancer Hospital

Recruiting

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Hubei Cancer Hospital

Not yet recruiting

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Breast Cancer
Fujian Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Immunotherapy Gastroesophageal Junction

China
Hunan Cancer Hospital

Recruiting

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Triple Negative Breast Neoplasms

China
Henan Cancer Hospital

Not yet recruiting

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Metastatic Colon Cancer
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Hunan Cancer Hospital

Recruiting

Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Herpesvirus 4, Human

China
Zhejiang Cancer Hospital

Recruiting

Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Rectal Cancer

China
Henan Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Zhejiang Cancer Hospital

Recruiting

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Adjuvant Radiotherapy

China
Zhejiang Cancer Hospital

Recruiting

Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients

Elderly Patients

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Zhejiang Cancer Hospital

Recruiting

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone

Liver Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Cervical Cancer
Zhejiang Cancer Hospital

Recruiting

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Hubei Cancer Hospital

Recruiting

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Nausea With Vomiting Chemotherapy-Induced

China
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hubei Cancer Hospital

Recruiting

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Radiotherapy | Immunotherapy | Advanced Non-Small Cell Squamous Lung Cancer

China
Hubei Cancer Hospital

Recruiting

Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

Metastatic Lung Cancer | Elderly Patients

China
Zhejiang Cancer Hospital

Recruiting

XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Double Hit Lymphoma | Triple Hit Lymphoma

China
Henan Cancer Hospital

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Fujian Cancer Hospital

Recruiting

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Carcinoma | Cervix Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Hepatocellular Carcinoma
Henan Cancer Hospital

Recruiting

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Squamous Cell Carcinoma of the Skin

China
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
Fujian Cancer Hospital

Recruiting

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Gastric Cancer
Henan Cancer Hospital

Recruiting

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Second Line Treatment of Gastric Cancer
Fujian Cancer Hospital

Not yet recruiting

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Solid Tumor
Hunan Cancer Hospital

Recruiting

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Esophageal Cancer
Henan Cancer Hospital

Not yet recruiting

Application of Antiosteoporosis Therapy in Osteolysis

Complication | Limb; Fusion

China
Zhejiang Cancer Hospital

Recruiting

DLCS for Predicting Neoadjuvant Chemotherapy Response

Gastric Cancer | Deep Learning | Neoadjuvant Chemotherapy | CT Images | Tumor Regression Grade

China
Henan Cancer Hospital

Not yet recruiting

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Gastric Cancer | Gastroesophageal-junction Cancer

3

Subscribe